Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeHealth

      Health

      MediPharm Labs Sets Date to Report Third Quarter 2026 Financial Results
      Health

      MediPharm Labs Sets Date to Report Third Quarter 2026 Financial Results

      November 6, 2026
      LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026
      Health

      LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026

      November 6, 2026
      POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
      Health

      POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

      November 6, 2026
      InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
      Health

      InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

      November 6, 2026
      Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
      Health

      Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

      November 6, 2026
      Solventum Reports Third Quarter 2026 Financial Results
      Health

      Solventum Reports Third Quarter 2026 Financial Results

      November 6, 2026
      Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook
      Health

      Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

      November 5, 2026
      AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS
      Health

      AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS

      November 5, 2026
      GLOBE LIFE INC. DECLARES DIVIDEND
      Health

      GLOBE LIFE INC. DECLARES DIVIDEND

      November 5, 2026
      Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
      Health

      Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

      November 5, 2026
      « 1 … 6 7 8 9 10 … 277 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026